Fractyl Health, Inc. - Common Stock (GUTS)
Competitors to Fractyl Health, Inc. - Common Stock (GUTS)
Elysium Health, Inc.
Elysium Health focuses on developing dietary supplements that support metabolic health, which puts them in competition with Fractyl Health's therapeutics aimed at similar health issues. While Fractyl is delving into pharmaceutical and clinical solutions, Elysium leverages a more consumer-oriented approach through wellness products. Fractyl may have an advantage in the clinical evidence supporting its therapies, while Elysium attracts customers looking for preventive measures through supplementation.
Inspira Health
Inspira Health offers a comprehensive suite of services related to obesity management, including surgical and non-surgical options. They provide holistic treatments that blend medical therapy with surgical interventions, competing directly with Fractyl Health's offerings. While Fractyl specializes in innovative metabolic therapeutics, Inspira leverages its extensive patient network and diversified service offerings, which can be considered a competitive advantage due to established trust and comprehensive care pathways.
LivaNova PLC LIVN +1.13%
LivaNova specializes in medical devices that address various health issues, including obesity, through device-based interventions. They compete with Fractyl by offering alternative technologies that manage weight and associated metabolic conditions. LivaNova's established reputation and diverse product portfolio give it a competitive advantage, allowing it to cater to a wider range of clients and providing a robust alternative to Fractyl's more targeted therapies.
Medtronic plc MDT -1.43%
Medtronic is a global leader in medical technology and has a presence in the diabetes market, which includes solutions for obesity management. Their wide-ranging portfolio and established distribution channels provide them with a significant advantage over Fractyl Health. While Fractyl is focused on specific innovations and therapies, Medtronic's vast resources and global scale allow it to reach a broader audience, making it a formidable competitor in the metabolic health space.
Obalon Therapeutics, Inc.
Obalon Therapeutics focuses on developing intragastric balloon devices for weight loss, targeting the same obesity and metabolic health market as Fractyl Health. Both companies aim to provide innovative solutions for obesity treatment and metabolic disorders. However, Obalon's technology relies on non-surgical interventions, which attracts a different demographic than Fractyl’s potentially more invasive approaches. While both companies prioritize patient health, Obalon's existing FDA approval for their device gives it a competitive edge in the market.